RE:PanCan and Precision Promise fails FibroGenPamrevlumab is a human monoclonal antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in clinical development for the treatment of metastatic pancreatic cancer, locally advanced pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). Pamrevlumab is an investigational drug and not approved for marketing by any regulatory authority.
FibroGen is in partnership with AstraZeneca in the marketing and development of its products in China.
https://www.fibrogen.com/our-strategy